Comparative Pharmacology
Head-to-head clinical analysis: RYZNEUTA versus ZARXIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RYZNEUTA versus ZARXIO.
RYZNEUTA vs ZARXIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Granulocyte colony-stimulating factor, acts on hematopoietic cells by binding to G-CSF receptors, stimulating proliferation, differentiation, and release of neutrophils.
ZARXIO (filgrastim-sndz) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to specific cell surface receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
6 mg subcutaneously once per chemotherapy cycle, administered approximately 24 hours after cytotoxic chemotherapy. Do not administer within the period from 14 days before to 24 hours after administration of cytotoxic chemotherapy.
5 mcg/kg subcutaneously once daily. Round to nearest vial size (300 mcg/0.5 mL or 480 mcg/0.8 mL).
None Documented
None Documented
The terminal elimination half-life is approximately 20–30 hours in healthy volunteers and up to 40 hours in cancer patients receiving chemotherapy, reflecting FcRn-mediated recycling and delayed clearance.
Terminal elimination half-life is approximately 3.5-4.5 hours in healthy adults; prolonged in renal impairment (up to 40 hours in end-stage renal disease).
Renal clearance accounts for approximately 70% of total clearance, with the remainder via hepatic/biliary/fecal routes. Unchanged drug is minimal as efbemalenograstim alfa is a recombinant fusion protein expected to undergo catabolism to small peptides and amino acids.
Primarily renal (70-80% as unchanged drug) via glomerular filtration; biliary/fecal excretion is negligible (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor